| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | 9-카바모일-9-(2-시아노에틸)플루오렌유도체의 제조방법 | KR1019810001317 | 1981-04-17 | KR1019840001071B1 | 1984-07-31 | 에드워드랄프라바니노; 안드류조셉피크; 잭베우포드캠프벨 |
| Fluorenecarboxamides were alkylated by acrylonitrile to yield amides I(R and R independently are H, alkyl, F, Cl; R2 and R3 independently are H, alkyl). Thus, 9-fluorenecarboxamide was treated with acrylonitrile in dioxane contg. PhCH2N+Me3OH- to give I(R=R1=R2=R3=H), and a mixt. of the latter and Me2CHNH2 was hydrogenated over Pt oxide to give amino amide II, which exhibited antiarrhythmic activity. | ||||||
| 182 | 페녹시 페닐 아미노산 유도체 및 그 조성물의 제조 방법 | KR1019820003561 | 1982-08-07 | KR1019840001130A | 1984-03-28 | 디에테르뒤르 |
| 내용없음 | ||||||
| 183 | 9-카바모일-9-(2-시아노에틸)플루오렌유도체의 제조방법 | KR1019810001317 | 1981-04-17 | KR1019830005110A | 1983-07-23 | 에드워드랄프라바니노; 안드류조셉피크; 잭베우포드캠프벨 |
| 내용없음 | ||||||
| 184 | TW107129207 | 2018-08-22 | TW201929670A | 2019-08-01 | KITAYAMA JUN; OYAMA KATSUAKI; FUKUCHI TOSHIKI | |
| Provided are an agricultural and horticultural agent having an improved effect on a bacterial disease damage of plants caused by Ralstonia solanacearum and the like, which are considered as an uncontrollable disease damage and become severe problems at a production site, and a control method using the same. The present invention applies a phenylacetonitrile derivative defined in formula [1].(In the formula, R1 represents a hydrogen atom, a C1-C3 alkyl group, or COCF3, R2 represents a hydrogen atom, a C1-C3 alkyl group, or a halogen atom, R3 and R5 each independently represent a hydrogen atom or a halogen atom, R4 represents a hydrogen atom, a halogen atom, a phenoxy group, or a C1-C3 alkyl group, and R6 represents a hydrogen atom). | ||||||
| 185 | 作為免疫調節劑之化合物 | TW104111833 | 2015-04-13 | TW201623221A | 2016-07-01 | 查帕克 路易斯S; CHUPAK, LOUIS S.; 丁 敏; DING, MIN; 馬丁 史考特W; MARTIN, SCOTT W.; 鄭 曉帆; ZHENG, XIAOFAN; 希瓦瓦山 皮亞希那; HEWAWASAM, PIYASENA; 康納利 提摩西P; CONNOLLY, TIMOTHY P.; 徐 寧寧; XU, NINGNING; 楊 革新; YEUNG, KAP-SUN; 朱 汝良; ZHU, JULIANG; 蘭利 大衛R; LANGLEY, DAVID R.; 坦尼 丹尼爾J; TENNEY, DANIEL J.; 史格拉 保羅 麥可; SCOLA, PAUL MICHAEL |
| 本發明概言之係關於作為免疫調節劑之化合物。本發明提供化合物、包括該等化合物之組合物及其使用方法。本發明另外係關於包括至少一種本發明化合物之醫藥組合物，其可用於治療包含癌症及感染性疾病之各種疾病。 | ||||||
| 186 | AMMOXIDATION CATALYST WITH SELECTIVE CO-PRODUCT HCN PRODUCTION | PCT/US2017/053364 | 2017-09-26 | WO2018071166A1 | 2018-04-19 | BRAZDIL, James F.; TOFT, Mark A.; SEELY, Michael J.; BESECKER, Charles J.; LIN, Sean S.-Y. |
A catalytic composition and process useful for the conversion of an olefin selected from the group consisting of propylene, isobutylene or mixtures thereof, to acrylonitrile, methacrylonitrile, hydrogen cyanide and acetonitrile and mixtures thereof, wherein the catalyst exhibiting increased selectivity to hydrogen cyanide compared to prior art catalysts. |
||||||
| 187 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | PCT/AU2017/050784 | 2017-07-28 | WO2018018091A1 | 2018-02-01 | DUGGAN, Karen Annette |
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions. |
||||||
| 188 | QUENCH COLUMN OPERATION AND BOTTOM PROCESSING | PCT/US2015/047873 | 2015-09-01 | WO2016053549A1 | 2016-04-07 | MCDONEL, Timothy Robert; COUCH, Jay Robert; WAGNER, David Rudolph; WACHTENDORF, Paul Trigg |
Processes are provided for quench column operation and bottom processing. A process for providing an ammonium sulfate stream includes conveying a reactor effluent to a quench column; and conveying sulfuric acid to the quench column to provide a quench column bottoms stream having about 10 weight percent or less polymer, and wherein an amount of ammonium sulfate and an amount of polymer are defined by a formula y = -M1x + C1 where y is a weight % of ammonium sulfate, x is a weight % polymer, M1 is 4.6 or less and C1 is 45 or less. |
||||||
| 189 | COMPOSITIONS COMPRISING NON-ACIDIC BOSWELLIA OIL FRACTION AS A BIO-ENHANCER FOR ENHANCING THE BIOAVAILABILITY OF BIOLOGICAL AGENTS | PCT/IN2011000364 | 2011-05-26 | WO2011151840A3 | 2012-01-26 | GOKARAJU GANGA RAJU; GOKARAJU RAMA RAJU; GOKARAJU VENTAKA KANAKA RANGA RAJU; GOLAKOTI TRIMURTULU; BHUPATHIRAJU KIRAN; ALLURI VENTAKA KRISHNA RAJU |
| The invention relates to Boswellia derived fraction selected from non-acidic Boswellia low polar gum resin extract fraction (BLPRE), Boswellia volatile oil fraction (BVOIL) or Boswellia oil fraction (BOIL) comprising BLPRE and BVOIL in combination with biological agents for enhancing the bioavailability of said biological agents. The invention also provides composition(s) comprising at least one component selected from Boswellia oil (BOIL), Boswellia volatile oil (BVOIL) and Boswellia low polar gum resin extract (BLPRE) in combination with a biological agent for increasing the bioavailability of biological agent. | ||||||
| 190 | METHOD FOR ISOLATING METHYLGLYCINENITRILE-N,N-DIACETONITRILE | PCT/IB2010/054382 | 2010-09-29 | WO2011042836A1 | 2011-04-14 | Judat, Bernd; Oftring, Alfred; Stamm, Armin; Teich, Friedhelm |
A method for isolating methylglycinenitrile-N,N-diacetonitrile (MGDN) from an aqueous mixture comprising MGDN is provided The method comprises cooling the aqueous mixture in one or more steps In one of these steps the mixture is cooled at a cooling rate of at least 20K/h from a temperature above the solidification point of MGDN to a temperature below the solidification point of MGDN The method is implemented continuously |
||||||
| 191 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | PCT/IB2010/000040 | 2010-01-12 | WO2010079423A1 | 2010-07-15 | BANDYOPADHYAY, Santu; PAL, Bikas, Chandra; PARASURAMAN, Jaisankar; ROY, Siddhartha; CHAKRABOTRY, Jayashree, Bagchi; MUKHERJEE, Indrani, Choudhury; MAHATO, Sanjit, Kumar; KONAR, Aditya; RAKSHIT, Srabanti; MANDAL, Labanya; GANGULY, Dipyaman; PAUL, Kausik; MANNA, Anirban; VINAYAGAM, Jayaraman; PAL, Churala |
The present invention relates to compounds of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention further relates to a method of treating malignancy by inhibition of PI3-Akt pathway and or induction of NO by administration of compound or said composition to a mammal in need thereof. |
||||||
| 192 | AN IMPROVED PROCESS FOR PRODUCTION OF BICALUTAMIDE USEFUL IN THE TREATMENT OF PROSTATE CANCER | PCT/IN2008000820 | 2008-12-08 | WO2009087666A3 | 2009-12-30 | KUDARAVALLI RAJA RAO; RAMBATHRI MURALIDHAR |
| The invention relates to an improved process for production of Bicalutamide useful in the treatment of prostate cancer by oxidizing N[4-Cyano-3-trifluoromethyl)phenyl]-3-[(4-fluorophenyl)thio]-2-hydroxy-2-methyl propanamide with Hydrogenperoxide in the presence of ethylacetate as solvent, methanesulfonic acid and sodiumtungstate as catalysts, washing the reaction mixture with sodiumthiosulphate solution or sodium metabisulphite solution, charcolising and evaporating the reaction mixture adding hydrocarbon solvent, cooling to room temperature and filtering. | ||||||
| 193 | SELECTIVE ANDROGEN RECEPTOR MODULATORS, ANALOGS AND DERIVATIVES THEREOF AND USES THEREOF | PCT/US2007016311 | 2007-07-19 | WO2008011072A3 | 2008-06-05 | DALTON JAMES T; MILLER DUANE D; RAKOV IGOR; BOHL CASEY; MOHLER MICHAEL L |
| This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including,inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders. | ||||||
| 194 | HALO ACTIVE AROMATIC SULFONAMIDE ORGANIC COMPOUNDS AND ODOR CONTROL USES THEREFOR | PCT/US2006033248 | 2006-08-25 | WO2007027524A3 | 2007-09-13 | SCHNEIDER DAVID J; SCHNEIDER CHARLES A |
| Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used halogen sulfonamide organic compound for these applications is Chloramine-T. This invention deals with the new use of discovered compositions of matter, halo active aromatic sulfonamide organic compounds and use of solutions of these compounds as, odor control agents. The odor control solutions may be buffered to a predetermined pH. The odor control compositions may further incorporate small percentages of low molecular weight alcohols and wetting agents. | ||||||
| 195 | ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS | PCT/US2005/035560 | 2005-10-03 | WO2006041797A3 | 2006-04-20 | LIN, Linus, S.; LIU, Ping |
The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. |
||||||
| 196 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | PCT/IN2003/000401 | 2003-12-29 | WO2005063693A1 | 2005-07-14 | JASTI, Venkat; VEERA REDDY, Arava; RAJENDIRAN, Chinnapillai; MD, QADEERUDDIN, md, samiuddin |
The invention disclosed in this application relates to an improved process for the preparation of the Entacapone which comprises. (i)reacting 3-alkoxy- 4-hydroxy-5-nitrobenzadehyde with N,N-diethylaminocyanoactamide in the presence of mild acid catalyst and a solvent at a temperature in the range of 50-115 °C, to get the 3-O-alkylated (methyl or ethyl) Entacapone and treating with acid catalysts in the presence of organic base and solvents at temperature in the range of 20-60 °C to get Entacapone. |
||||||
| 197 | PROCESS FOR THE SYNTHESIS OF 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXYNAPHTHONITRILE | PCT/US2004028645 | 2004-09-02 | WO2005026105A2 | 2005-03-24 | WU YANZHONG; REN JIANXIN; GHOSH MOUSUMI; LEVENT MAHMUT; SUTHERLAND KAREN WIGGINS; RAVEENDRANATH PANOLIL |
| A process for making a compound of formula I wherein R1, is CN, F or CI; R2 is H or Br; and R3 and R4 are each independently H or F. These compounds are useful in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis. | ||||||
| 198 | CHEMICAL COMPOUNDS | PCT/US2004/018252 | 2004-06-09 | WO2005000795A2 | 2005-01-06 | BLANC, Jean-Baptiste, E.; CADILLA, Rodolfo; COWAN, David, John; KALDOR, Istvan; LARKIN, Andrew, L.; STEWART, Eugene, Lee; TURNBULL, Philip, Stewart; TRUMP, Ryan, Paul |
This invention relates to non-steroidal compounds that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. |
||||||
| 199 | DESODORIERUNG VON KATIONISCHEN ACETONITRILDERIVATEN | PCT/EP2003/005346 | 2003-05-22 | WO2003101940A2 | 2003-12-11 | SPECKMANN, Horst-Dieter; ASSMANN, Georg; LAHN, Wolfgang; POETHKOW, Jörg; MIDDELHAUVE, Birgit; BLASEY, Gerhard; WERNER, Helga; LUSSE, Michael |
Bei der Herstellung und der Lagerung von Lösungen kationischer Nitrile der allgemeinen Formel (I) in der R1 für -H, -CH3, einen C2-24-Alkyl- oder -Alkenylrest, einen substituierten C2-24-Alkyl- oder -Alkenylrest mit mindestens einem Substituenten aus der Gruppe -Cl, -Br, -OH, -NH2, -CN, einen Alkyl- oder Alkenylarylrest mit einer C1-24-Alkylgruppe, oder für einen substituierten Alkyl- oder Alkenylarylrest mit einer C1-24-Alkylgruppe und mindestens einem weiteren Substituenten am aromatischen Ring steht, R2 und R3 unabhängig voneinander ausgewählt sind aus -CH2-CN, -CH3, -CH2-CH3, -CH2-CH2-CH3, -CH(CH3)-CH3, -CH2-OH, -CH2-CH2-OH, -CH(OH)-CH3, -CH2-CH2-CH2-OH, -CH2-CH(OH)-CH3, -CH(OH)-CH2-CH3, -(CH2CH2-O)nH mit n = 1, 2, 3, 4, 5 oder 6, R4 und R5 unabhängig voneinander eine voranstehend für R1, R2 ober R3 angegebene Bedeutung haben und X ein ladungsausgleichendes Anion ist, sollte das Auftreten geruchsintensiver Minderbestandteile vermieden werden. Dies gelingt durch das Einwirkenlassen einer Kombination aus einer Percarbonsäure, einer Carbonsäure und Wasserstoffperoxid. |
||||||
| 200 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PCT/IB0201217 | 2002-04-08 | WO02088069A9 | 2003-12-04 | DAMON DAVID BURNS; DUGGER ROBERT WAYNE; SCOTT ROBERT WILLIAM |
| This invention relates compounds of formulae Wherein A is CN,CONH>2< OR CONHCOOR, R being methyl or optionally substituted benzyl, useful as intermediates for cholesteryl ester transfer protein (CETP) inhibitors and methods for the preparation thereof. | ||||||
